Exploration of the association of KRAS status and risk stratification with metastasis
KRAS-mutant, RS, KRAS-wild
REGRESSION, LUNG METASTASIS
We first explored the differences in clinical characteristics and prognosis between the KRAS-wild and KRAS-mutant groups (Table 
Clinical characteristics and prognosis of the KRAS-wild-type and KRAS-mutant groupsCEA: Carcinoembryonic antigenUsing a cut-off of 0.679, the patients were stratified into a high RS group and a low RS group. The clinical features and prognoses of the patients in the high and low RS groups are shown in supplementary Table We conducted Cox regression to further explore this relationship. The median follow-up duration was 38.1 months (interquartile range: 26.9, 49.4). Seven (10.45%) wild-type KRAS patients developed lung metastasis during follow-up, compared to 11 (28.95%) patients with KRAS mutations (HR 3.225, 95% CI 1.249, 8.323, 
Kaplan–Meier survival curves for patients with lung metastasis in the 